surmount-1 tirzepatide non-diabetic obesity trial SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes Weight reduction with different doses

Mild nausea Reduced appetite Constipation Bloating or fullness Fatigue Mild dizziness Occasional diarrhea Feeling full after much smaller meals Not every patient develops side effects, and many continue their normal daily activities with only minor changes in appetite

Changes like adjusting your dose or exploring other options can help, but they usually work best after youve dialed in the basics

Rights and permissions About this article Cite this article Covarrubias, A.J., Perrone, R., Grozio, A

Emerging medications and the expanding toolbox The field is evolving rapidly

Schedule A Free Consultation What is Tirzepatide

This is the question nobody on page 1 answers directly